Why AbbVie Stock Was Getting Mashed on Monday

Core Insights - AbbVie experienced a significant decline in stock value, dropping 12% following disappointing results from a schizophrenia drug trial [1] - The emraclidine treatment failed to meet its primary endpoint in a phase 2 trial, showing no statistically significant improvement over a placebo [2] - AbbVie expressed disappointment over the trial results but remains committed to analyzing the data for future steps [3] Acquisition Context - AbbVie recently acquired Cerevel Therapeutics for $8.7 billion, with the emraclidine drug being a key motivation for the acquisition [4] - The acquisition included other pipeline programs, notably the promising Parkinson's disease treatment tavapadon, which has shown positive results in late-stage trials [5]